All Articles
3 FEATURE Indication Withdrawals of Small Molecule Inhibitors from the Accelerated Approval Program
The United States Food and Drug Administration’s (FDA) Accelerated Approval Program, which expedites approval of drugs and biologics that treat serious conditions such as cancer, has drawn criticism for allowing products to reach the market only to see th
2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
The in-person annual Transplantation & Cellular Therapy Meetings of ASTCT™ (American Society for Transplantation and Cellular Therapy) and CIBMTR® (Center for International Blood and Marrow Transplant Research) took place from February 15-19, 2023 in Orla
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Talazoparib plus enzalutamide resulted in clinically meaningful and statistically significant improvement in rPFS versus standard of care enzalutamide as first-line treatment for patients with mCRPC.
Professional Cancer Associations Collaborate to Improve Treatment of Anemia in Adult Patients with Myelodysplastic Syndromes
The initiative will provide support and guidance to community hematologists/oncologists on the risk-stratification of MDS, selection of evidence-based and novel therapies for the management of anemia in patients with lower-risk MDS, and on best practices
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Among patients undergoing allogeneic HLA-matched HSCT with reduced-intensity conditioning, GVHD-free, relapse-free survival at 1 year was significantly more common among those who received cyclophosphamide–tacrolimus–mycophenolate mofetil.